Literature DB >> 20457609

Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity.

Galit Lazer1, Liron Pe'er, Marganit Farago, Kazuya Machida, Bruce J Mayer, Shulamit Katzav.   

Abstract

The guanine nucleotide exchange factor (GEF) Vav1 is an essential signal transducer protein in the hematopoietic system, where it is expressed physiologically. It is also involved in several human malignancies. Tyrosine phosphorylation at the Vav1 amino terminus plays a central role in regulating its activity; however, the role of carboxyl terminal tyrosine residues is unknown. We found that mutation of either Tyr-826 (Y826F) or Tyr-841 (Y841F) to phenylalanine led to loss of Vav1 GEF activity. When these Vav1 mutants were ectopically expressed in pancreatic cancer cells lacking Vav1, they failed to induce growth in agar, indicating loss of transforming potential. Furthermore, although Y841F had no effect on Vav1-stimulated nuclear factor of activated T cells (NFAT) activity, Y826F doubled NFAT activity when compared with Vav1, suggesting that Tyr-826 mediates an autoinhibitory effect on NFAT activity. SH2 profiling revealed that Shc, Csk, Abl, and Sap associate with Tyr-826, whereas SH2-B, Src, Brk, GTPase-activating protein, and phospholipase C-gamma associate with Tyr-841. Although the mutations in the Tyr-826 and Tyr-841 did not affect the binding of the carboxyl SH3 of Vav1 to other proteins, binding to several of the proteins identified by the SH2 profiling was lost. Of interest is Csk, which associates with wild-type Vav1 and Y841F, yet it fails to associate with Y826F, suggesting that loss of binding between Y826F and Csk might relieve an autoinhibitory effect, leading to increased NFAT. Our data indicate that GEF activity is critical for the function of Vav1 as a transforming protein but not for NFAT stimulation. The association of Vav1 with other proteins, detected by SH2 profiling, might affect other Vav1-dependent activities, such as NFAT stimulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457609      PMCID: PMC2906301          DOI: 10.1074/jbc.M109.094508

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  Tyrosine kinases as targets for cancer therapy.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  Sos, Vav, and C3G participate in B cell receptor-induced signaling pathways and differentially associate with Shc-Grb2, Crk, and Crk-L adaptors.

Authors:  L Smit; G van der Horst; J Borst
Journal:  J Biol Chem       Date:  1996-04-12       Impact factor: 5.157

3.  Lck regulates Vav activation of members of the Rho family of GTPases.

Authors:  J Han; B Das; W Wei; L Van Aelst; R D Mosteller; R Khosravi-Far; J K Westwick; C J Der; D Broek
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor.

Authors:  K D Fischer; Y Y Kong; H Nishina; K Tedford; L E Marengère; I Kozieradzki; T Sasaki; M Starr; G Chan; S Gardener; M P Nghiem; D Bouchard; M Barbacid; A Bernstein; J M Penninger
Journal:  Curr Biol       Date:  1998-05-07       Impact factor: 10.834

5.  Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis.

Authors:  Martin E Fernandez-Zapico; Natalia C Gonzalez-Paz; Ellen Weiss; Doris N Savoy; Julian R Molina; Rafael Fonseca; Thomas C Smyrk; Suresh T Chari; Raul Urrutia; Daniel D Billadeau
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

6.  The adaptor protein 3BP2 binds human CD244 and links this receptor to Vav signaling, ERK activation, and NK cell killing.

Authors:  Ifigènia Saborit-Villarroya; Juana M Del Valle; Xavier Romero; Enric Esplugues; Pilar Lauzurica; Pablo Engel; Margarita Martín
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

Review 7.  Vav-family proteins in T-cell signalling.

Authors:  Victor L J Tybulewicz
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

8.  Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product.

Authors:  P Crespo; K E Schuebel; A A Ostrom; J S Gutkind; X R Bustelo
Journal:  Nature       Date:  1997-01-09       Impact factor: 49.962

9.  Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.

Authors:  S Katzav
Journal:  Oncogene       Date:  1993-07       Impact factor: 9.867

10.  A functional T-cell receptor signaling pathway is required for p95vav activity.

Authors:  J Wu; S Katzav; A Weiss
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

View more
  14 in total

1.  Vav1 Regulates T-Cell Activation through a Feedback Mechanism and Crosstalk between the T-Cell Receptor and CD28.

Authors:  Ynes A Helou; Anna P Petrashen; Arthur R Salomon
Journal:  J Proteome Res       Date:  2015-06-16       Impact factor: 4.466

2.  Tyrosine phosphorylation-dependent localization of TmaR that controls activity of a major bacterial sugar regulator by polar sequestration.

Authors:  Tamar Szoke; Nitsan Albocher; Sutharsan Govindarajan; Anat Nussbaum-Shochat; Orna Amster-Choder
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

3.  Vav1 in hematologic neoplasms, a mini review.

Authors:  Matthew J Oberley; Deng-Shun Wang; David T Yang
Journal:  Am J Blood Res       Date:  2012-01-01

4.  Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling.

Authors:  Kazuya Machida; Malik Khenkhar; Peter Nollau
Journal:  Genes Cancer       Date:  2012-05

5.  Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF Vav1.

Authors:  Gina L Razidlo; Yu Wang; Jing Chen; Eugene W Krueger; Daniel D Billadeau; Mark A McNiven
Journal:  Dev Cell       Date:  2013-03-25       Impact factor: 12.270

6.  Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Surendra Dasari; Yu Zeng; Guangzhen Hu; Ryan A Knudson; Patricia T Greipp; Jaime I Davila; Sarah H Johnson; Julie C Porcher; James B Smadbeck; Bruce W Eckloff; Daniel D Billadeau; Paul J Kurtin; Mark A McNiven; Brian K Link; Stephen M Ansell; James R Cerhan; Yan W Asmann; George Vasmatzis; Andrew L Feldman
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

7.  Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation.

Authors:  Lena Ilan; Shulamit Katzav
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

8.  SH3 domain tyrosine phosphorylation--sites, role and evolution.

Authors:  Zuzana Tatárová; Jan Brábek; Daniel Rösel; Marian Novotný
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

9.  Structure analysis between the SWAP-70 RHO-GEF and the newly described PLD2-GEF.

Authors:  Julian Gomez-Cambronero
Journal:  Small GTPases       Date:  2012-08-03

10.  ERK positive feedback regulates a widespread network of tyrosine phosphorylation sites across canonical T cell signaling and actin cytoskeletal proteins in Jurkat T cells.

Authors:  Ynes A Helou; Vinh Nguyen; Samantha P Beik; Arthur R Salomon
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.